Cantex’s CX-01 gets FDA orphan drug status to treat acute myeloid leukemia

This article was originally published here

Cantex Pharmaceuticals has secured orphan drug designation from the US Food and Drug Administration (FDA) for CX-01 to treat acute myeloid leukemia (AML).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply